The Paradox of Senescence in Glioblastoma: SASP as an Emerging Cancer Hallmark
Cancers · 08.02.2026 · 18 (4) · 550
DOI: 10.3390/cancers18040550 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 08.02.2026. Verfasst von Wataru Tarumi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Neuroscience, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Cellular senescence has been traditionally viewed as a tumor-suppressive program that halts its proliferation in response to oncogenic stress or DNA damage. However, recent studies have highlighted a paradoxical role for senescence in glioblastoma (GBM), IDH-wildtype, the most aggressive primary brain tumor in adults. Accumulating evidence indicates that senescence represents a “frequent and durable” cell fate in GBM, particularly following standard therapies such as temozolomide and radiotherapy. Senescent cells frequently persist after temozolomide or radiotherapy and acquire a senescence-associated secretory phenotype (SASP) composed of inflammatory cytokines, growth factors and matrix-remodeling enzymes. These factors not only promote tumor cell survival with stemness-induction but also reshape the pro-tumorigenic microenvironment with metabolic rewiring and immune evasion. Notably, senescence also arises in non-malignant cells—including astrocytes, endothelial cells, microglia, and infiltrating immune cells—creating a multicellular senescent niche that fuels recurrence. Here, we describe a recent advance in our understanding of senescence and SASP in the pathobiology of GBM. We further focus on a state-of-the-art, challenging exploration of the idea that single-cell and spatial profiling, capable of identifying senescence- and SASP-associated morphologic and heterogeneous states, will further refine patient selection and therapeutic timing. By reframing senescence as a modifiable determinant of GBM evolution, this review underscores its emerging significance as both a cancer hallmark and a therapeutic vulnerability.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Integrative Neuroscience, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan.
- Department of Pathology, Tokyo Women's Medical University, Shinjuku, Tokyo 162-8666, Japan.
ORCID-Profile: Yasukazu Nakahata, Kenta Masui
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Tarumi, W., Murai, K., Nakahata, Y., & Masui, K. (2026). The Paradox of Senescence in Glioblastoma: SASP as an Emerging Cancer Hallmark. Cancers, 18(4), 550. https://doi.org/10.3390/cancers18040550
Vancouver
Tarumi W, Murai K, Nakahata Y, Masui K. The Paradox of Senescence in Glioblastoma: SASP as an Emerging Cancer Hallmark. Cancers. 2026;18(4):550. doi:10.3390/cancers18040550
BibTeX
@article{Tarumi2026,
author = {Tarumi, Wataru and Murai, Kiyohito and Nakahata, Yasukazu and Masui, Kenta},
title = {The Paradox of Senescence in Glioblastoma: SASP as an Emerging Cancer Hallmark},
journal = {Cancers},
year = {2026},
volume = {18},
number = {4},
pages = {550},
doi = {10.3390/cancers18040550}
}
EUVIMED